A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Salivary Gland Tumor
Urothelial Carcinoma
Ovarian Carcinoma
Breast Cancer
Soft Tissue Sarcoma

Interventions

DRUG: AVA6000

Sponsor

Avacta Life Sciences Ltd